期刊
ONCOTARGET
卷 7, 期 27, 页码 41274-41284出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8978
关键词
hepatocellular carcinoma(HCC); phosphorylated extracellular signaling-regulated kinase(pERK); programmed death receptor-1 (PD-1); sorafenib
资金
- National 973 Plan for Basic Research [2015CB553803]
- National Natural Science Foundation of China [81201942]
- Zhejiang Provincial Natural Science Foundation of China [LZ14H160002, Y15H160103]
Sorafenib is a multikinase inhibitor approved as the first line treatment for late stage hepatocellular carcinoma (HCC). Due to its significant variation in clinical benefits among patients, defining prognostic biomarkers for sorafenib sensitivity in HCC would allow targeted treatment. Phosphorylated extracellular ignaling-regulated kinase (pERK) was proposed to predict the response to sorafenib in HCC, but clinical supports are mixed or even contradictory. Here we found that pERK expression levels are variable in different nodules from individual patient liver. Xenografts derived from resected tumors are resistant to sorafenib inhibition when expressing low levels of pERK. This correlation of low pERK levels and sorafenib resistance is corroborated by histological characterization of chemical-induced and genetic mouse models for pERK-positive and pERK-negative HCC respectively, as well as computed tomography (CT) imaging of patient tumors with validated pERK expression. Mouse and human HCC samples expressing low pERK show strong inflammatory infiltrating cells and significant enrichment of intratumoral CD8(+) cytotoxic T lymphocytes that express programmed death receptor-1 (PD-1). These pERK-PD-1(+) patients have poorer overall and disease-free survival than pERK(+)PD-1(-) patients. In conclusion, our data suggest that anti-PD-1 immunotherapy might complement sorafenib in treating HCC patients by targeting sorafenib-resistant cancer cells, and the dual pERK and PD-1 biomarkers would help HCC patient selection to achieve optimal clinical benefits.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据